Amyloid-Beta Solubility in the Treatment of Alzheimer’s Disease

There is general agreement that Alzheimer’s disease will become a crisis by the middle of the century. The Alzheimer’s Association estimates that 5 million Americans currently have Alzheimer’s disease and that their loved ones devote nearly 18 billion hours annually toward their care. If Alzheimer’s disease remains unchecked, these numbers are projected to more than triple by 2050, and the economic burden will exceed $1 trillion per year. The quest to find an effective therapy has been urgent. For nearly two decades, since the first report of a successful amyloid-beta (Aβ) immunotherapy in mice,1 this goal has seemed tantalizingly close. . . .